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receptor ligand-binding domain 2)-transduced hepatocytes (YAP-Hc). Yap (yes-associated protein) nu-
clear translocation/function in YAP-Hc was regulated by tamoxifen. Repopulating YAP-Hc and host
hepatocytes were fluorescence-activated cell sorting-purified and their transcriptomic profiles compared
by RNAseq. After 1 year of liver repopulation, YAP-Hc clusters exhibited normal morphology, inte-
gration into hepatic plates and hepatocyte-specific gene expression, without dysplasia, dedifferentiation,
or tumorigenesis. RNAseq analysis showed up-regulation of 145 genes promoting cell proliferation and
305 genes suppressing apoptosis, including hepatocyte growth factor and connective tissue growth factor
among the top 30 in each category and provided insight into the mechanism of cell competition that en-
abled replacement of host hepatocytes by YAP-Hc. In Gunn rats transplanted with YAP-Hc+tamoxifen,
there was a 65%-81% decline in serum bilirubin over 6 months versus 8%-20% with control-Hc, represent-
ing a 3-4-fold increase in therapeutic response. This correlated with liver repopulation as demonstrated
by the presence of Ugt1a1-positive hepatocyte clusters in livers and western blot analysis of tissue ho-
mogenates. Conclusion: Tamoxifen-regulated nuclear translocation/function of hYAP-ERT2 enabled
long-term repopulation of DPPIV−/− and Gunn rat livers by hYAP-ERT2-transduced hepatocytes with-
out tumorigenesis. This cell transplantation strategy may offer a potential therapy for most of the
inherited monogenic liver diseases that do not exhibit liver injury.
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Genes and Pathways Promoting 
Long-Term Liver Repopulation 
by Ex Vivo hYAP-ERT2 Transduced 
Hepatocytes and Treatment of Jaundice in 
Gunn Rats
Esther A. Peterson,1* Zsuzsanna Polgar,1* Gnanapackiam S. Devakanmalai,1 Yanfeng Li,1 Fadi L. Jaber,1 Wei Zhang,2 Xia Wang,1 
Niloy J. Iqbal,3 John W. Murray,4 Namita Roy-Chowdhury,1,5 Wilber Quispe-Tintaya,5 Alexander Y. Maslov,5  
Tatyana L. Tchaikovskaya,1 Yogeshwar Sharma,1 Leslie E. Rogler,1 Sanjeev Gupta,1,6 Liang Zhu,1,3 Jayanta Roy-Chowdhury ,1,5 
and David A. Shafritz1,6,7
Hepatocyte transplantation is an attractive alternative to liver transplantation. Thus far, however, extensive liver 
repopulation by adult hepatocytes has required ongoing genetic, physical, or chemical injury to host liver. We hy-
pothesized that providing a regulated proliferative and/or survival advantage to transplanted hepatocytes should en-
able repopulation in a normal liver microenvironment. Here, we repopulated livers of DPPIV− (dipeptidyl peptidase-4) 
rats and Ugt1a1 (uridinediphosphoglucuronate glucuronosyltransferase 1a1)-deficient Gunn rats (model of Crigler-
Najjar syndrome type 1), both models without underlying liver injury, for up to 1 year by transplanting lenti-hYAP-
ERT2 (mutated estrogen receptor ligand-binding domain 2)-transduced hepatocytes (YAP-Hc). Yap (yes-associated 
protein) nuclear translocation/function in YAP-Hc was regulated by tamoxifen. Repopulating YAP-Hc and host 
hepatocytes were f luorescence-activated cell sorting–purified and their transcriptomic profiles compared by RNAseq. 
After 1 year of liver repopulation, YAP-Hc clusters exhibited normal morphology, integration into hepatic plates and 
hepatocyte-specific gene expression, without dysplasia, dedifferentiation, or tumorigenesis. RNAseq analysis showed 
up-regulation of 145 genes promoting cell proliferation and 305 genes suppressing apoptosis, including hepatocyte 
growth factor and connective tissue growth factor among the top 30 in each category and provided insight into the 
mechanism of cell competition that enabled replacement of host hepatocytes by YAP-Hc. In Gunn rats transplanted 
with YAP-Hc+tamoxifen, there was a 65%-81% decline in serum bilirubin over 6 months versus 8%-20% with con-
trol-Hc, representing a 3-4-fold increase in therapeutic response. This correlated with liver repopulation as demon-
strated by the presence of Ugt1a1-positive hepatocyte clusters in livers and western blot analysis of tissue homogenates. 
Conclusion: Tamoxifen-regulated nuclear translocation/function of hYAP-ERT2 enabled long-term repopulation of 
DPPIV−/− and Gunn rat livers by hYAP-ERT2-transduced hepatocytes without tumorigenesis. This cell transplanta-
tion strategy may offer a potential therapy for most of the inherited monogenic liver diseases that do not exhibit 
liver injury. (Hepatology Communications 2019;3:129-146).
Liver transplantation has markedly improved survival in patients with acute liver failure, end-stage liver disease, and inherited metabolic liver diseases.(1) As liver transplantation involves major surgery and is limited by donor organ short-age, transplantation of isolated primary hepatocytes 
Abbreviations: CN1, Crigler-Najjar syndrome type 1; Ctg f, connective tissue growth factor; DPPIV, dipeptidyl peptidase-4; EMT, epithelial-
mesenchymal transition; ERT2, mutated estrogen receptor ligand-binding domain 2; FACS, fluorescence activated cell sorting; GGT, γ-glutamyl 
transpeptidase; GSEA, Gene Set Enrichment Analysis; H&E, hematoxylin and eosin; Hg f, hepatocyte growth factor; IHH, Indian hedgehog; 
IPA, Ingenuity Pathway Analysis; Ntcp, sodium taurocholate cotransporter protein; RHA, Roman high avoidance; TEADs, TEA domain family 
members 1-4 transcription factors; TGFβ1, transforming growth factor beta 1; TTR, transthyretin; Ugt1a1, uridinediphosphoglucuronate 
glucuronosyltransferase 1a1; WT, wild type; YAP, yes-associated protein; YAP-Hc, hYAP1-ERT2-transduced donor hepatocytes.
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has been evaluated as a minimally invasive alternative 
to whole-organ transplantation.(2) Although mod-
est amelioration of several monogenic liver diseases 
by hepatocyte transplantation has been reported, the 
number of hepatocytes that can engraft in the liver 
after introduction into the portal venous system is 
limited and unmodified adult primary hepatocytes 
do not proliferate significantly in uninjured host liv-
ers.(3,4) However, engrafted hepatocytes can prolifer-
ate extensively in genetically manipulated animals, 
such as urokinase plasminogen activator–transgenic(5) 
or Fah−/− (fumarylacetoacetate-hydrolase knockout) 
mice(6) in which there is massive and continuous 
death of host hepatocytes, which provides a pro-
liferative stimulus to transplanted wild-type (WT) 
hepatocytes. Less severe chronic hepatocellular stress 
also provides a proliferative advantage to trans-
planted cells, as observed in PiZ (alpha-1 antitrypsin 
Z protein) mice that are transgenic for a misfolded 
human α1-antitrypsin variant(7) and the Long-Evans 
Cinnamon rat model of Wilson’s disease.(8) However, 
in most monogenic liver diseases, such as Crigler-
Najjar syndrome type 1 (CN1), ornithine transcar-
bamylase deficiency, familial hypercholesterolemia, 
phenylketonuria, and coagulation factors VII and IX 
deficiency, there is no significant liver injury, whereby 
transplanted hepatocytes have no proliferative advan-
tage over host hepatocytes and the mass of integrated 
hepatocytes remains insufficient to cure the disease.
Prolonged genotoxic injury of host liver induced by 
plant alkaloids, such as retrorsine(3) or monocrotaline(9) 
or hepatic X-irradiation(4) together with proliferative 
stimuli, such as partial hepatectomy or liver growth 
factors like hepatocyte growth factor (HGF), permits 
extensive repopulation by transplanted hepatocytes. 
We hypothesized that competitive liver repopulation 
could also occur if engrafted hepatic cells possessed 
cell-intrinsic proliferative and/or survival advantage 
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over host cells. We demonstrated this by transplanting 
isolated fetal liver stem/progenitor cells into normal 
adult livers.(10) Subsequently, we enhanced liver repop-
ulation by adult hepatocytes transduced ex vivo with 
lentivirus transthyretin (TTR) human YAP1 fused 
with a modified ERT2 (mutated estrogen receptor 
ligand-binding domain 2) before transplantation.(11)
YAP (yes-associated protein) regulates liver size by 
promoting cell proliferation and inhibiting apopto-
sis.(12,13) In resting cells, YAP localizes in the cyto-
plasm, where it undergoes phosphorylation- dependent 
degradation through Hippo signaling. When the 
Hippo pathway is turned off by cell proliferative sig-
nals, YAP translocates to the nucleus, where it binds 
to and activates TEADs (TEA domain family mem-
bers 1-4 transcription factors).(12,13) The hYAP1-
ERT2 fusion protein remains in the cytoplasm, but 
following tamoxifen administration, it translocates to 
the nucleus,(11) where it binds to TEADs, activating 
its transcriptional function. As increased proliferative 
potential of transplanted cells raises concerns of can-
cer risk, we engineered this system so that the nuclear 
transcription/activity of YAP could be tightly con-
trolled by tamoxifen administration.
To determine the duration and extent of liver 
repopulation by hepatocytes lentivirally transduced 
with hYAP-ERT2 (YAP-Hc) and to elucidate its 
molecular underpinnings, we transplanted YAP-Hc 
from dipeptidyl peptidase IV+ F344 rats (DPPIV+/+) 
into congenic DPPIV−/− recipients and used RNAseq 
with isolated YAP-Hc and host Hc from repopu-
lated rat livers at 1 year to identify specific genes and 
pathways promoting liver repopulation. To evaluate 
whether this repopulation strategy can be used to 
treat an animal model of a human metabolic liver dis-
ease with no underlying liver injury, we transplanted 
WT Wistar-RHA (Roman high-avoidance) rat 
YAP-Hc into Ugt1a1 (uridinediphosphoglucuronate 
glucuronosyltransferase 1a1)-deficient jaundiced Gunn 
rats, a model of CN1, and showed progressive and 
marked reduction of serum bilirubin following liver 
repopulation.
Materials and Methods
animals
Inbred Wistar-RHA rats congenic with Ugt1a1-
deficient Gunn rats were maintained in the Animal 
Models, Stem Cells, and Cell Therapy Core of the 
Liver Research Center. Inbred DPPIV+ F344 rats, 
purchased from Taconic Farms (Germantown, NY), 
were used as hepatocyte donors for DPPIV−/− F344 
rats. All procedures were approved by the Institutional 
Animal Care and Use Committee, Albert Einstein 
College of Medicine, and were carried out in a humane 
manner in accordance with approved guidelines. Rats 
were fed a diet containing 400 mg/kg tamoxifen 
citrate prepared by Bio-Serve (Frenchtown, NJ) or 
normal rodent chow, as indicated. Animals receiving 
tamoxifen did not show histological evidence of liver 
injury.
HepatoCyte isolation, 
reComBinant lentiVirus 
proDuCtion, lentiViral 
transDuCtion oF primary 
rat HepatoCytes, rna 
isolation, real-time 
polymerase CHain reaCtion, 
anD QuantitatiVe real-time 
polymerase CHain reaCtion
All procedures were performed as previously 
reported.(11)
gunn rats: eXperimental 
groups
Adult (200 g) Gunn rats of both genders were sub-
jected to 66% hepatectomy and stratified into various 
experimental groups described in Fig. 7A and the 
Supporting Information.
staining oF liVer seCtions
Procedures for hematoxylin and eosin (H&E) 
staining, immunofluorescent and immunohistochem-
ical staining, and histochemical staining for DPPIV 
and γ-glutamyl transpeptidase (GGT) are described 
in the Supporting Information.
FluoresCenCe-aCtiVateD 
Cell sorting
To separate host DPPIV−/− liver hepatocytes from 
hepatocytes derived from transplanted DPPIV+ donor 
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cells, we performed fluorescence-activated cell sorting 
(FACS) using two antibodies: (1) anti-DPPIV mouse 
monoclonal antibody (Santa Cruz Biotechnology Inc., 
Dallas, TX) plus secondary goat anti-mouse-Alexa 
488 conjugated antibody ( Jackson lmmunoResearch 
Laboratories, West Grove, PA), and (2) phycoeryth-
rin-conjugated anti-ICAM antibody to identify 
hepatocytes (Invitrogen, Thermo Fisher Scientific). 
Isotype-matched irrelevant (control) antibodies were 
used to determine background staining. Fifty thou-
sand cells were sorted into two groups: ICAM+/
DPPIV+ (ID) repopulating hepatocytes and ICAM+/
DPPIV− (I) host hepatocytes. FACS-purified hepato-
cytes were immersed into Qiazol for RNA extraction 
(Supporting Information).
rna preparation 
For seQuenCing oF 
transCriptome rna 
liBraries, seQuenCe Data 
aCQuisition, proCessing, anD 
analysis
See Supporting Information.
ploiDy analysis
To determine the ploidy state of repopulating 
YAP-Hc and host hepatocytes, we analyzed the DNA 
content with Hoechst 33258 dye staining in tissue 
sections from 3 rats at 1 year after cell transplantation 
(Supporting Information).
statistiCs
Data are shown as mean ± SEM. Statistical signif-
icance was determined by a two-tailed Student t test.
Results
yap-Hc progressiVely 
repopulate tHe liVer oF 
DppiV− F344 reCipients For 12 
montHs
The duration and extent of liver repopulation by 
YAP-Hc was determined in DPPIV− rats (Fig. 1A) 
with tamoxifen administration continuously in the 
food for up to 12 months. As shown by DPPIV 
enzyme histochemistry, the number of DPPIV+ clus-
ters were similar at 6 and 12 months, but repopulating 
clusters was much larger at 12 months (Fig. 1B, left 
panels). Morphometric quantification showed 3.56% 
± 0.90% and 13.84% ± 2.80% hepatocyte replacement 
at 6 and 12 months, respectively (Fig. 1B, middle 
panel), representing a 4-fold increase at 12 months 
(P = 0.024) and no reduction in liver repopulation 
when tamoxifen feeding was discontinued during 
the second 6 months after YAP-Hc transplantation 
(Fig. 1B, right panel).
liVer morpHology remaineD 
normal aFter yap-Hc/
tamoXiFen-inDuCeD liVer 
repopulation
H&E staining and DPPIV/YAP immunohisto-
chemistry after 12 months of repopulation showed 
normal liver lobular structure (Fig. 1C). YAP-Hc were 
fully integrated into hepatic parenchyma without 
compressing or distorting the surrounding liver tissue. 
Donor cell clusters were indistinguishable from host 
hepatocytes, except for DPPIV and YAP expression 
(Fig. 1C,D) and showed normal cell surface mem-
brane polarity (i.e., DPPIV expression on the apical 
domain and either Ntcp [sodium taurocholate cotrans-
porter protein] [Fig. 1E] or Oatp1a1 [organic anion 
transport protein 1a1] [Fig. 1F]) on the baso-lateral 
domain of transplanted cells. Repopulating YAP-Hc 
and host hepatocytes were oriented in the same direc-
tion in the parenchymal plates, as demonstrated by 
the pattern of green immunostaining in the baso- 
lateral domain of both cell types, better illustrated 
with Ntcp (Fig. 1E).
ploiDy state oF 
repopulating yap-HC Was 
similar to tHat oF Host 
HepatoCytes
Analysis of DNA content of both YAP-Hc and 
host hepatocytes in same tissue sections (Fig. 2A) 
from 3 rats 1 year after cell transplantation showed 
that 2N(diploid), 4N(tetraploid), and 8N+(octaploid) 
classes were similar for donor and host hepatocytes: 
35% versus 35%, 55% versus 57%, and 9% versus 7%, 
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respectively (P > 0.99) (Fig. 2B). Modal DNA content 
across these ploidy classes was also similar (Fig. 2C-
E). This analysis did not show emergence of new sub-
classes with intermediate DNA content within diploid 
(2-3.9N), tetraploid (4-7.9N), or octaploid (8-16N) 
classes in repopulating YAP-Hc, indicating that there 
was no increase in aneuploidy in transplanted hepato-
cytes over neighboring host hepatocytes.
Fig. 1. Repopulation of normal rat liver by lenti-TTR-hYAP-ERT2-transduced hepatocytes 1 year after cell transplantation. (A) 
Schematic diagram of hepatocyte transplantation protocol. (B) Detection of WT DPPIV+ repopulating hepatocyte clusters in DPPIV− 
recipients by enzyme histochemistry. (C,D) Analysis of consecutive sections by H&E staining and DPPIV/Yap immunohistochemistry 
1 year after cell transplantation (C = ×10 magnification; D = ×40 magnification). (E,F) Demonstration of hepatocyte cell-surface 
membrane polarity and orientation of transplanted cells in the parenchymal plates using double-label immunohistochemistry for 
DPPIV and Ntcp (E) or Oatp1a1 (F). Abbreviations: LTR, long terminal repeat.
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repopulating Clusters 
eXpress HepatoCyte-speCiFiC 
proteins, But not marKers 
oF HepatiC progenitors, 
Biliary epitHelium, or 
HepatoCellular CarCinoma
Immunofluorescence staining of liver sections 12 
months after YAP-Hc transplantation showed that 
DPPIV+ clusters were positive for YAP and hepato-
cyte-specific proteins (albumin, HNF4α, and asialo-
glycoprotein receptor) (Fig. 3A). In contrast, markers 
of hepatic progenitor cells or biliary epithelial cells 
(CK-19, SOX9, and EpCAM) or hepatocellular car-
cinoma (Afp, CD133, and CD44) were undetectable 
in hepatocytes (Fig. 3A). Vimentin-positive cells were 
equally distributed in host liver and repopulating 
DPPIV+ cluster regions, but YAP-Hc were vimen-
tin-negative. YAP-Hc were also negative for desmin 
and α-smooth muscle actin, indicating absence of epi-
thelial-mesenchymal transition (EMT).
no liVer FiBrosis or FoCal 
noDular transFormation oF 
Donor HepatoCyte Clusters
H&E, trichrome, and sirius red staining in consec-
utive sections of liver 12 months after cell transplan-
tation showed normal liver histology and no evidence 
of fibrosis in recipient liver or DPPIV+ clusters (Fig. 
3B). Staining for GGT that is normally expressed in 
bile duct epithelial cells and is a classic marker for 
focal nodular transformation of hepatocytes,(14) and 
DPPIV by enzyme histochemistry in serial sections 
showed that host bile duct epithelial cells stained 
positive for GGT, but YAP-Hc clusters were nega-
tive (Fig. 3C). Taken together, data in Figs. 2 and 3 
indicate that repopulating YAP-Hc clusters exhibit 
Fig. 2. Ploidy class distribution at 1 year in YAP-Hc and host hepatocytes. (A) Staining of nuclei in 5-um tissue sections with Hoechst 
33258 dye (blue) and the cell surface of transplanted YAP-Hc with DPPIV antibody (green). (B) Ploidy classes in YAP-Hc and host 
hepatocytes (n = 3 rats) were similarly distributed (n = number of hepatocytes counted; black bars = donor [DPPIV+] cells; gray bars = 
host [DPPIV−] cells). P values were determined by Wilcoxon rank sum test. (C-E) Ploidy distribution profiles in 2N, 4N, and 8+N cell 
populations showed no statistically significant difference in modal DNA content in YAP-Hc versus host hepatocytes in these three 
subclass populations. Therefore, new subclasses with intermediate DNA content were not observed in YAP-Hc.
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Fig. 3. Histochemical analysis of liver tissue 1 year after cell transplantation for hepatic gene expression. (A) The specific protein 
paired with DPPIV and the f luorescent color generated by second antibody are given for each panel. (B) Histochemical analysis 
of YAP-Hc transplanted tissue for hepatic fibrosis by H&E, trichrome, and sirius red staining. (C) DPPIV and GGT staining in 
consecutive sections of rat liver 1 year after YAP-Hc transplantation, showing GGT staining of bile duct epithelial cells and scattered 
cells in hepatic parenchyma. All hepatocytes in DPPIV+ clusters are GGT negative and all bile ducts are DPPIV negative.
peterson, polgar, et al. Hepatology CommuniCations, January 2019
136
a normal mature hepatocyte phenotype, without evi-
dence of dysplasia, dedifferentiation, transdifferenti-
ation, EMT, or preneoplastic transformation 1 year 
after cell transplantation.
Cell Competition BetWeen 
yap-Hc anD Host HepatoCytes
Immunofluorescent staining for Ki-67, a cell prolif-
eration marker, showed that at both 6 and 12 months 
after cell transplantation, the proliferation rate was 
approximately 3-fold higher in YAP-Hc-derived 
DPPIV+ clusters, compared with surrounding host 
hepatocytes (P = 0.002 and P = 0.02, respectively) 
(Fig. 4A-D). In contrast, 3-fold to 4-fold fewer cells 
in repopulating clusters were engaged in apoptosis 
compared with host hepatocytes (shown by staining 
for active caspase-3) at 6 months (P = 0.008) and 
12 months (P = 0.04) (Fig. 4E-H). (See Supporting 
Table S1 for numbers of animals used, cells counted 
for Ki67 and active caspase-3, and percentage of total 
cells in each category.) These differences in prolifer-
ation and apoptosis of YAP-Hc versus host hepato-
cytes at both 6 months and 12 months indicate a cell 
competition-like mechanism.(15)
genome-WiDe transCriptome 
analysis oF yap-Hc Versus 
Host HepatoCytes
Hepatocytes isolated from repopulated livers at 
3 months and 6 months following transplantation 
were FACS-purified into I-CAM1+/DPPIV− host 
hepatocytes (I) and I-CAM1+/DPPIV+ repopulat-
ing YAP-Hc (ID) and showed total separation of 
these two cell populations (Fig. 5A). Using RNAseq, 
we compared normalized read counts from 4 donor/
recipient pairs isolated at 3 months and 6 months, 
Fig. 4. Detection and quantification of proliferating and apoptotic transplanted versus host hepatocytes by f luorescent 
immunohistochemistry for Ki67 and active caspase-3. (A,B) Merged immunofluorescent images for DPPIV (red) and Ki67 (green) 
at 6 months (A) and 12 months (B) (blue = nuclei stained with DAPI [4 ,´6-diamidino-2-phenylindole]). (C,D) Quantification of 
proliferating (Ki67+) hepatocytes in DPPIV+ repopulating clusters and DPPIV− host hepatocytes by Image J analysis at 6 months and 12 
months after cell transplantation. (E,F) Merged immunofluorescent images for DPPIV (red) and active caspase-3 (green) at 6 months 
(E) and 12 months (F) after cell transplantation. (G,H) The percentage of apoptotic cells was about 3-fold higher in DPPIV− host 
hepatocytes compared with DPPIV+ transplanted hepatocytes at both 6 months (G) and 12 months (H). P values for (C), (D), (G), and 
(H) were determined by two-tailed Student t test.
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Fig. 5. RNAseq analysis of FACS-sorted YAP-Hc and host hepatocytes. (A) FACS: Hepatocytes were isolated according to positivity 
for ICAM-1 (marker for all hepatocytes) and DPPIV (marker for donor hepatocyte). P5, ICAM-1+/DPPIV+: left panel, donor 
hepatocytes; right panel, donor progeny in 6-month repopulated liver. P6, ICAM-1+/DPPIV−: middle panel, host hepatocytes; right 
panel, host hepatocytes in 6-month repopulated liver; left panel, hepatocytes from DPPIV+ donor rat. (B) Integrative Genomic Viewer 
display of reads mapping to YAP1. Read counts from individual RNAseq libraries are displayed for ICAM+/DPPIV+ (ID) and ICAM+/
DPPIV− (I) hepatocyte pairs. The human YAP1 sequence is displayed. Nucleotide color code: A, green; T, red; C, blue; G, umber. 
Sequence locations exhibiting a difference between human YAP1 and rat Yap1 are highlighted. In the boxed nucleotide position, the 
rat nucleotide is C = blue, whereas the human nucleotide is G = umber. (C) GSEA plot of YAP-conserved signature in RNAseq data 
from ICAM+/DPPIV+ (ID) and ICAM+/DPPIV− (I) pairs. (D) Clustergram of the log2RAT ID/I in the 8 donor/host pairs for genes 
contained in the YAP-conserved signature. (E) Clustergram displaying the log2 RAT ID/I for genes known to be downstream of YAP 
activation. Significantly up-regulated genes are marked red, unregulated genes are marked blue, down-regulated genes are marked 
green, and inconsistent changes between 3-month and 6-month samples are marked black.
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respectively. Both YAP-Hc (ID) and host (I) popu-
lations showed typical hepatocyte gene-expression 
profiles with albumin messenger RNA expressed 
at the highest level (Supporting Table S2). Using 
the Integrative Genomics Viewer (Broad Institute, 
Cambridge, MA), specific expression of hYAP1 was 
identified by comparing the read counts in regions of 
the YAP gene, in which there are single nucleotide dif-
ferences between human and rat Yap (Fig. 5B). hYAP 
sequences were found only in ICAM+/DPPIV+ (ID) 
cells (Fig. 5B). For example, in the boxed region of 
Fig. 5B, all YAP-Hc (ID) preparations showed both 
the human nucleotide G (umber) and rat nucleotide 
C (blue) at this position, whereas all host hepatocyte 
preparations (I) showed only rat nucleotide C (blue). 
Similar results were obtained for hERT2 versus rat 
ESR1 (estrogen receptor 1) reads at specific locations 
where nucleotide changes were observed (Supporting 
Fig. S1).
To determine whether hYAP-ERT2 transgene 
expression altered endogenous gene expression, we 
compared the normalized read count obtained by the 
RNA-seq of YAP-Hc to that of host hepatocytes. Of 
the 2,080 significantly regulated genes in YAP-Hc 
in all 8 donor/recipient pairs (P ≤ 0.001), 2,026 were 
up-regulated and 55 genes were down-regulated 
(Supporting Fig. S2). Supporting Table S3 lists all 
significantly regulated genes and their relative regu-
lation. We used the Gene Set Enrichment Analysis 
(GSEA, Broad Institute)(16,17) to determine whether 
known YAP targets were induced in YAP-Hc. Of 
the two published YAP target gene signatures, YAP1 
UP(18) and YAP/TAZ conserved,(19) our Yap signa-
ture best matched the latter (normalized enrichment 
score = 1.81, false discovery rate q value = 0.001) (Fig. 
5C). Twenty-seven of the 50 genes in the YAP/TAZ 
conserved signature were significantly up-regulated in 
YAP-Hc (P ≤ 0.001) (Fig. 5D, red letters).
To understand how YAP expression alters the 
molecular and cellular behavior of YAP-Hc, we que-
ried RNAseq data for regulated expression of YAP/
TAZ transcriptional co-activators and downstream 
effectors in YAP-Hc (Fig. 5E). WWTR (Taz) 
was up-regulated 1.9 fold at 6 months. YAP1 and 
WWTR1 bind to TEADs. TEADs 1, 2, and 3 were 
not significantly regulated in YAP-Hc. Binding of 
Yap/Taz to Tead1 increases expression of amino acid 
transporters, Slc7a5 and Slc38a1, which are essential 
for mTorc-mediated growth regulation and participate 
in hepatocarcinogenesis.(20,21) However, Slc7a5 and 
Slc38a1 were not up-regulated in YAP-Hc (Fig. 5E). 
It has also been reported that increased WWTR1 
expression induces Indian hedgehog (IHH), which 
leads to increased inflammation and hepatic fibro-
sis.(22) Interestingly, IHH expression was decreased 
in YAP-Hc (Fig. 5E), at the borderline of statistical 
significance (P = 0.053).
Tead4 expression was up-regulated 12.4-fold in 
YAP-Hc (Fig. 5E). Tead4 is part of a cascade that 
leads to activation of Dlc1, a potent tumor suppres-
sor that inhibits cell growth and tumorigenicity in 
hepatocellular carcinoma cells.(23) Dlc1 has RhoGAP 
(GTPase activating protein) activity, which suppresses 
cell growth and directional migration during devel-
opment.(24) Yap/Tead4, in concert with Ap1, induces 
Tns3, which binds to and activates Dlc1 to inhibit 
Rhoa as part of its tumor suppressor function.(23,24) 
Tns3 and Dlc1 are significantly up-regulated in 
YAP-Hc (2.77 fold and 1.56 fold, respectively) (Fig. 
5E). By comparing our data to the cancer genome 
landscape,(25) we identified five other tumor suppres-
sors that are significantly up-regulated in YAP-Hc: 
Prdm1, Kdm6a, Tnfa1p3, Atm, and Msh2 (Supporting 
Table S3). We used GSEA to generate a gene sig-
nature for YAP-Hc (Fig. 6A). The top 50 up-regu-
lated genes in this signature included four known Yap 
targets: Emp2, Dab2, Tead4, and Marcks. Among the 
top 50 down- regulated genes in YAP-Hc (Fig. 6A) 
are LGR5, a marker of a progenitor phenotype,(26) 
and Prom1 (CD133), a known tumor progenitor cell 
gene.(27)
We used the phenotype prediction analysis algo-
rithm of Ingenuity Pathway Analysis (IPA) to gain an 
understanding of cellular processes affected by tamox-
ifen-induced hYAP expression in YAP-Hc. We found 
145 genes that promote cell proliferation are up-reg-
ulated in repopulating YAP-Hc (P ≤ 0.001); Hgf and 
Ctgf (connective tissue growth factor) are among the 
top 30 (Fig. 6B). Hgf and Ctgf are also among the 
top 30 of 305 up-regulated genes that are known to 
suppress apoptosis (Fig. 6B). In addition, IPA analysis 
revealed significant enrichment of eight canonical sig-
naling pathways, including the Rho family GTPases, 
integrins, NFκB (nuclear factor kappa B), HGF, VEGF 
(vascular endothelial growth factor), WNT/β-catenin, 
STAT3 (signal transducer and activator of transcrip-
tion 3), and ERK (extracellularly regulated kinase)/
MAPK (p38 mitogen-activated protein kinases) 
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(Fig. 6C). Interestingly, although the WNT signal-
ing pathway is significantly enriched, β-catenin is not 
up-regulated in YAP-Hc, due to increased expression 
of five inhibitors of WNT signaling, including Dkk, 
Sfrp1, Apc, Sox, and Rar (Supporting Fig. S3). These 
pathways play important roles in controlling cell pro-
liferation, migration, tissue remodeling and apopto-
sis, all of which are important for liver repopulation. 
Fig. 6. GSEA and IPA analysis of RNAseq from ID/I pairs isolated at 3 months and 6 months following transplantation. (A) Heat 
map showing the top 50 most significantly up-regulated and down-regulated genes in ID/I pairs (red arrows, up-regulated genes 
specifically mentioned in text; blue arrows, down-regulated genes specifically mentioned in text). (B) Selected results from phenotype 
prediction analysis (IPA) identifying the top 30 genes in significantly enriched categories that promote cell proliferation and suppress 
apoptosis (red arrows highlight Ctgf and Hgf, which are among the top 30 genes in both categories). (C) Graph depicting significantly 
enriched canonical pathways identified using IPA. Shown are pathways with significantly positive Z scores and P values less than 
0.001. Values shown are the log (P value) for each pathway. (D) Results of upstream regulator analysis (IPA) identifying upstream 
regulators that are significantly up-regulated in YAP-Hc with significantly positive Z scores and P values less than 0.001. (E) Putative 
gene network identified by upstream regulator analysis (IPA) that controls the cellular behavior of YAP-Hc during liver repopulation.
peterson, polgar, et al. Hepatology CommuniCations, January 2019
140
Hepatology CommuniCations, Vol. 3, no. 1, 2019 peterson, polgar, et al.
141
However, WNT signaling and β-catenin expression, 
which are up-regulated in hepatobiliary carcinogen-
esis,(28) are not up-regulated in our liver repopulation 
model, using hYAP-ERT2-transduced hepatocytes in 
a normal liver tissue microenvironment.
Finally, we used the upstream regulator prediction 
algorithm of IPA to identify potential upstream reg-
ulators that are significantly regulated by tamoxifen in 
YAP-Hc. These selected specific upstream regulators 
include Tgfβ1 (transforming growth factor beta 1), Hgf, 
Nfκb1, and Ctgf (Fig. 6D). Using this analysis, we iden-
tified a network of regulators that represents a cascade 
of gene regulation, which may be important in control 
of the regenerative response induced by tamoxifen in 
YAP-Hc. In our data set, YAP-Hc show up-regulated 
Hgf and Ctgf signaling with cross-talk between Yap 
downstream regulators Tgfβ1, Vegfa, p38 Mapk, Erk1/2 
and Iκbκb, all of which up-regulate expression of spe-
cific genes affecting cell proliferation (Fig. 6E).
preFerential proliFeration 
oF Wistar-rHa yap-Hc 
transplanteD into gunn 
rat liVers
We evaluated the engraftment and proliferation of 
transplanted Wistar-RHA hepatocytes by immuno-
fluorescence staining of liver sections for rat Ugt1a1 
and western blot analysis, using the experimental 
groups shown schematically in Fig. 7A. Hepatocytes 
in donor Wistar-RHA rats were positive for Ugt1a1 
(Fig. 7B-i), whereas hepatocytes in untreated Gunn 
rats were negative (Fig. 7B-ii). With transplanted 
nontransduced/nontamoxifen-treated Wistar-RHA 
hepatocytes, engrafted Ugt1a1+ cells were seen as 
single cells or doublets (Fig. 7B-iii). When Gunn rats 
were transplanted with YAP-Hc under continuous 
tamoxifen feeding, large clusters of Ugt1a1+ hepato-
cytes were produced (Fig. 7B-iv); such proliferation 
did not happen in the absence of tamoxifen (Fig. 7B-
v). Interestingly, when we started tamoxifen feeding 
6 months after YAP-Hc transplantation and contin-
ued tamoxifen for 6 more months, similar clusters of 
YAP-Hc were observed (Fig. 7B-vi).
repopulateD areas oF 
gunn rat liVer Were 
morpHologiCally normal
Repopulating YAP-Hc clusters in Gunn rat liver, 
stained with H&E or immunohistochemically for 
Ugt1a1 in consecutive sections, were histologically 
normal (Fig. 7C-i,ii). At ×40 magnification (Fig. 
7C-iii,iv), Ugt1a1 staining in repopulating hepato-
cytes exhibited characteristic “clumpy,” cytoplasmic 
distribution and enrichment in the nuclear envelope 
(Fig. 7C-iv), characteristic of its distribution in the 
endoplasmic reticulum.(29)
BotH yap-ert2 transDuCtion 
anD tamoXiFen 
aDministration are 
reQuireD to inCrease tHe 
mass oF Donor-DeriVeD ugt1a1+ 
HepatoCytes
Western blots of liver homogenates with antibody 
against rat Ugt1a1 showed an immunoreactive band of 
appropriate size in all Gunn rats that received hepato-
cyte transplantation (Fig. 8A), but was not found in 
Fig. 7. Gunn rat liver repopulation by transplanted Wistar-RHA rat hepatocytes. (A) Schematic diagram of five experimental Gunn 
rat groups: (a) transplanted with Wistar-RHA YAP-Hc followed by tamoxifen feeding; (b) similar to (a), but maintained on standard 
laboratory chow; (c) same as in (b), but switched to tamoxifen-containing diet after 6 months; (d) transplantation of nontransduced 
Wistar-RHA hepatocytes with tamoxifen feeding; and (e) transplantation of nontransduced Wistar-RHA hepatocytes, maintained on 
standard laboratory chow. (B) Immunofluorescence staining of rat liver sections for Ugt1a1: (i) Wistar-RHA donor rats; (ii) untreated 
Gunn rats, no transplantation; (iii) untreated Gunn rats, 8 months after transplanting nontransduced hepatocytes on standard lab 
chow; (iv) untreated Gunn rats, 8 months after transplanting Wistar-RHA YAP-Hc followed by tamoxifen feeding immediately after 
transplantation; (v) similar to (iv), but untreated Gunn rats maintained on standard lab chow; and (vi) similar to (v), but untreated Gunn 
rats switched to tamoxifen-containing diet 6 months after transplantation and followed for additional 6 months. (C) Normal liver 
histology and Ugt1a1 staining: (i) consecutive liver sections from a Gunn rat in group B-iv stained with H&E at ×20 magnification; 
(ii) consecutive liver sections from a Gunn rat in group B-iv immunohistochemically stained for Ugt1a1 at ×20 magnification; (iii) 
consecutive liver sections from a Gunn rat in group B-iv stained with H&E at ×40 magnification; and (iv) consecutive liver sections 
from a Gunn rat in group B-iv immunohistochemically stained for Ugt1a1 at ×40 magnification. showed normal liver histology and 
Ugt1a1 staining.
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nontransplanted Gunn rats (Fig. 8A, control Gunn 
lanes). β-Actin was used as internal control. The ratios 
of band intensities for Ugt1a1 and β-actin for each 
recipient Gunn rat liver was expressed as a percent-
age of that expressed in WT Wistar-RHA rats (Fig. 
8B). Liver homogenates from Gunn rats transplanted 
with Wistar-RHA YAP-Hc and fed tamoxifen either 
immediately after transplantation (Fig. 8A, a1-a3), 
or beginning 6 months later (Fig. 8A, c1-c3), con-
tained 8.25% ± 0.75% or 8.5% ± 0.8% of the Ugt1a1 
present in WT Wistar-RHA rat livers (Fig. 8B, bars 
a and c, respectively). These levels were 17-fold to 
35-fold greater than those found in Gunn rats that 
received YAP-Hc but no tamoxifen (Fig. 8A, b1-b3), 
nontransduced hepatocytes plus tamoxifen (Fig. 8A, 
d1-d3, and Fig. 8B, bars b and d, respectively), or 
hepatocytes without transduction or tamoxifen diet 
(Fig. 8A, e1-e3, and Fig. 8B, bar e), all with P < 0.02. 
These findings confirmed that expansion of trans-
planted Wistar-RHA YAP-Hc required both hYAP-
ERT2 expression and its tamoxifen-induced nuclear 
translocation/function.
serum BiliruBin reDuCtion 
parallels eXtent oF liVer 
repopulation By yap-Hc
Gunn rats subjected to partial hepatectomy with-
out hepatocyte transplantation exhibited increased 
serum bilirubin levels 2 weeks after partial hepa-
tectomy, which resolved by 4 weeks, followed by a 
gradual age-related increase (Fig. 8C-i). All groups 
of Gunn rats transplanted with Wistar-RHA rat 
hepatocytes exhibited reduced serum bilirubin at 
time points beyond 16 weeks after transplantation 
(Fig. 8C-ii-vi). In rats transplanted with nontrans-
duced Wistar-RHA hepatocytes without tamoxifen 
feeding (Fig. 8C-ii), with nontransduced Wistar-
RHA hepatocytes plus tamoxifen (Fig. 8C-iii.), or 
with Wistar-RHA YAP-Hc but no tamoxifen (Fig. 
8C-iv), long-term bilirubin reduction ranged from 
8% to 20% (14% ± 6%). In contrast, rats that received 
Wistar-RHA YAP-Hc with tamoxifen administra-
tion starting immediately after cell transplantation 
showed a 65%-81% (73% ± 8%) serum bilirubin 
reduction (Fig. 8C-v): values that are significantly 
different from those in rats transplanted with 
Wistar-RHA YAP-Hc without tamoxifen admin-
istration (Fig. 8C-iv) (P < 0.02), or nontransduced 
hepatocytes with (Fig. 8C-iii) or without (Fig. 8C-ii) 
tamoxifen (P < 0.02). Interestingly, serum bilirubin 
was markedly reduced when tamoxifen feeding was 
initiated 6 months after transplantation of Wistar-
RHA YAP-Hc (Fig. 8C-vi). After 20 to 24 weeks 
of tamoxifen administration, the hypobilirubinemic 
effect was similar to that attained by initiating tamox-
ifen feeding immediately after hepatocyte transplan-
tation (Fig. 8C-v). These results confirm tight off/
on control of YAP-ERT2 function by tamoxifen and 
indicate that engrafted YAP-Hc that had remained 
quiescent for a long time still retain proliferative 
responsiveness to tamoxifen.
Fig. 8. Hepatic Ugt1a1 content and metabolic effect in recipient Gunn rats. (A) Western blots for Ugt1a1 in liver homogenates from 
Gunn rats: Each lane represents an individual rat (Cont, untreated Gunn rat; a1-a3, 7.5 months to 12 months after Wistar-RHA YAP-
Hc transplantation; b1-b3, as in a1-a3 but maintained on standard lab chow; c1-c3, as in b1-b3 but tamoxifen diet started 6 months 
after transplantation; d1-d3, transplantation with nontransduced hepatocytes followed by tamoxifen feeding; e1-e3, as in d1-d3 but 
maintained on standard lab chow; RHA, liver homogenate of control Wistar-RHA rat (the amount of protein applied to this lane was 
25% of that used for other lanes). (B) Relative abundance of Ugt1a1: The ratio between the band densities of Ugt1a1 and β-actin was 
determined for each lane and expressed as a percentage of the Ugt1a1/β-actin ratio observed for Wistar RHA rats. Bars a-e show the 
means ± SDs of rats in the corresponding groups in (A) (n = 3). (C) Serum bilirubin levels: Serum bilirubin was determined before and 
at various intervals after hepatocyte transplantation. Each line represents an individual recipient Gunn rat, and each dot is the mean of 
triplicate determinations. All Gunn rats underwent partial hepatectomy and then were grouped as follows: i, control Gunn rats without 
hepatocyte transplantation; ii, transplanted nontransduced hepatocytes, without tamoxifen feeding; iii, transplanted nontransduced 
hepatocytes followed by tamoxifen feeding; iv, transplanted Wistar-RHA YAP-Hc on standard lab chow; v, transplanted Wistar-RHA 
YAP-Hc on tamoxifen feeding; and vi, transplanted Wistar-RHA YAP-Hc switched to tamoxifen feeding 6 months after hepatocyte 
transplantation. (D) High-performance liquid chromatography of bilirubin in bile samples: Bilirubin species in bile samples obtained 
at sacrifice were converted to ethylanthranilate azodipyrroles (Supporting Information). Representative tracings from individual rats 
from the various groups are shown. Note that the scales (ordinate) are different for different samples: i, Wistar-RHA rat; ii, Gunn rat 
without cell transplantation; iii, Gunn rat transplanted with nontransduced hepatocytes, maintained on standard lab chow; iv, Gunn 
rat transplanted with nontransduced Wistar-RHA hepatocytes plus tamoxifen feeding; v, Gunn rat transplanted with Wistar-RHA 
YAP-Hc plus tamoxifen feeding; and vi, Gunn rat transplanted with Wistar-RHA YAP-Hc, maintained on standard lab chow for 6 
months and then switched to tamoxifen feeding for 6 months.
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HepatoCyte 
transplantation in gunn 
rats resulteD in Biliary 
eXCretion oF BiliruBin 
gluCuroniDe
We next collected bile samples before euthanasia and 
converted bilirubin species to ethylanthranilate azo-
dipyrroles(30) for analysis by high-performance liquid 
chromatography (HPLC) (Supporting Information). 
As expected, the bile of WT Wistar-RHA rats 
yielded predominantly azodipyrrole glucuronides with 
a smaller amount of unconjugated azodipyrrole (Fig. 
8D-i). Bile from Gunn rats that underwent partial 
hepatectomy without cell transplantation produced 
only unconjugated azodipyrroles (Fig. 8D-ii). Bile 
from Gunn rats receiving Wistar-RHA hepatocytes 
yielded both azodipyrrole glucuronide and unconju-
gated azodipyrrole (Fig. 8D-iii,vi). However, in rats 
receiving both Wistar-RHA YAP-Hc and tamoxifen, 
the area under the curve of azodipyrrole glucuron-
ides was much increased and equaled that of uncon-
jugated azodipyrroles (Fig. 8D-v,vi). These findings 
independently confirmed a far greater repopulation 
of Gunn rat livers transplanted with Wistar-RHA 
YAP-Hc plus tamoxifen, compared with control 
Wistar-RHA hepatocytes, and demonstrated normal 
physiologic function of these cells in Gunn rats.
Discussion
We show that repopulation of normal rat liver by 
YAP-Hc is tightly controlled by tamoxifen feeding. 
Repopulation was increased 4-fold between 6 months 
and 12 months, demonstrating long-term prolifer-
ation of engrafted cells. Proliferating donor hepato-
cytes appeared morphologically normal, with normal 
cellular polarity and orientation within the hepatic 
plates without distortion or compression of surround-
ing parenchyma and without evidence of fibrosis, 
increased aneuploidy, or neoplastic transformation. 
Studies in Gunn rats showed that the bilirubin low-
ering effect of transplanted YAP-Hc was markedly 
enhanced (mean 73% reduction) only when tamoxifen 
was administered. Although serum bilirubin concen-
trations did not decline to levels in WT control rats, if 
the same percent reduction could be achieved in CN1 
patients, this would represent a major therapeutic 
benefit, as the risk of kernicterus would be removed 
without the need for phototherapy.
Mature hepatocytes transplanted into the liver 
through the portal venous system engraft in the liver 
as single cells or in small groups of 2 to 3 cells. In 
recipients without chronic liver injury, these cells 
undergo minimal proliferation even in response to 
66% partial hepatectomy, because host hepatocytes 
proliferate in parallel with donor hepatocytes. Thus, 
liver repopulation by transplanted cells depends on 
the balance between the proliferative potential and 
apoptotic behavior of host versus transplanted hepato-
cytes. Such competitive advantage for engrafted nor-
mal adult hepatocytes may preexist in some genetic 
diseases, such as hereditary tyrosinemia or α1-an-
titrypsin deficiency, in which host hepatocytes are 
undergoing chronic injury.(7) However, there is no 
underlying hepatocellular injury in many monogenic 
liver diseases. Here we present a strategy that per-
mits repopulation of host livers in a normal tissue 
microenvironment by providing donor cells with a 
pharmacologically controlled cell-intrinsic prolifera-
tive and survival advantage over host hepatocytes. At 
both 6 months and 12 months after cell transplanta-
tion, donor cell clusters contained significantly more 
Ki67-positive dividing cells and significantly fewer 
caspase 3–positive apoptotic cells (Fig. 4), indicating 
that enhanced proliferation and reduced cell death, 
the basic features of cell competition, are responsible 
for liver repopulation by YAP-Hc.
A major concern in studies that increase the prolif-
erative activity of transplanted cells is associated tumor 
risk. In a study of liver cell fate, Yimlamai et al.(31) 
noted that Yap expression was much higher in biliary 
epithelial cells than in adult hepatocytes, and when 
Yap expression in transgenic hepatocytes was induced 
by doxycycline, mature hepatocytes dedifferentiated, 
hepatobiliary progenitor genes were turned on, and 
the cells differentiated along the biliary lineage. High 
Yap expression favored a biliary phenotype; therefore, 
it was concluded that different Yap levels/activity 
could determine different hepatic cell fates.(31) Based 
on similar reasoning, we expressed hYAP-ERT2 under 
the TTR promoter, which is hepatocyte-specific and 
weaker than the TRE (tetracycline response element) 
promoter used by Yimlamai et al.,(31) and our exper-
iments were performed in a normal liver microenvi-
ronment. Both of these factors could contribute to the 
lack of hepatobiliary transdifferentiation.
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Other interesting findings revealed by RNAseq are 
that (1) Lrg5, a marker for stem and progenitor cells 
in many tissues including the liver,(26) is not hyperex-
pressed in repopulating hepatocytes; (2) Hg f and Ctg f 
are among the top 30 up-regulated cell proliferation 
and antiapoptotic genes in YAP-Hc; (3) YAP-Hc 
exhibit a Yap signature; (4) Tead4, which is in a sig-
naling pathway that activates a potent liver tumor 
suppressor, Dlc1, a tumor-suppressor gene,(20-24) was 
highly up-regulated (12.8 fold); and (5) both Tns3, 
a downstream Yap target, and Dlc1, which is acti-
vated by Tns3 binding, are up-regulated in YAP-Hc. 
Several other tumor-suppressor genes in the can-
cer genome landscape,(25) Prdm1, Kdm6a, Tnfa1P3, 
Atm and Msh2, are also significantly up-regulated in 
repopulating YAP-Hc. Finally, increased IHH expres-
sion, which is required for EMT and hepatic fibro-
sis,(22) was not hyperexpressed in YAP-Hc (Fig. 5E). 
Overall, these findings provide a molecular explana-
tion for the absence of dedifferentiation, hepatic pro-
genitor cell formation, hepatobiliary transformation, 
EMT, fibrosis, or carcinogenesis in our repopulation 
model. Furthermore, YAP/TAZ activation can induce 
negative feedback to regulate Hippo pathway homeo-
stasis,(32) which could, conceivably, limit the effect of 
tamoxifen-activated YAP-Hc. If true, tamoxifen-acti-
vated YAP-ERT2 would be sufficient for liver repop-
ulation by YAP-Hc but not for hepatocarcinogenesis.
Expression of HGF, an important cytokine in liver 
regeneration,(33) is regulated in YAP-Hc, an inter-
esting new finding that will require further study. 
We also found that several canonical signaling path-
ways that are important for control of cell behavior, 
including migration, remodeling, cell proliferation and 
apoptosis, are significantly enriched among the genes 
up-regulated in YAP-Hc (Fig. 6C). This, accompa-
nied by identification of a network of upstream regu-
lators (Fig. 6D,E), provides insight into how a small 
but continuous competitive advantage of YAP-Hc can 
lead to effective replacement of host hepatocytes with 
restoration of liver function, as demonstrated by the 
marked reduction of serum bilirubin in the Gunn rat 
model of CN1 (Fig. 8C,D).
In summary, our cell transplantation strategy 
enables long-term repopulation of livers without pre-
existing or induced liver injury. Repopulation is under 
tight pharmacological control and is not associated 
with distortion of liver architecture, hepatocyte dedif-
ferentiation, transdifferentiation, EMT, or neoplastic 
transformation. With further development, this strat-
egy could be useful in treating a large number of 
inherited metabolic disorders of the liver that are not 
associated with chronic liver injury.
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